Description:
Background:
Adoptive T cell therapy with tumor infiltrating lymphocytes (TILs) has been reported to
induce durable clinical responses in patients with metastatic melanoma. From patients own
tumor material T cells are extracted, expanded and activated in vitro in a 4-6 weeks culture
period. Before TIL infusion patients are preconditioned with a lymphodepleting
chemotherapeutic regimen. After TIL infusion, patients are treated with IL-2 to support T
cell activation and expansion in vivo.
The BRAF inhibitor is an approved treatment of metastatic melanoma and functions by
selectively inhibiting the BRAF mutated enzyme, consequently halting the proliferation of
tumor cells. Furthermore, in vitro tests have shown that vemurafenib has immunomodulatory
effects that are hypothesized to synergize with TIL therapy, which has been confirmed in
animal studies.
Objectives:
- To evaluate safety and feasibility when combining vemurafenib and ACT with TILs.
- To evaluate treatment related immune responses
- To evaluate clinical efficacy
Design:
- Patients will be screened with a physical exam, medical history, blood samples and ECG.
- Patients will start vemurafenib 960 mg BID and will continue during TIL preparation.
- 7 days after start of vemurafenib, patients will undergo surgery to harvest tumor
material for TIL production.
- Patient stops vemurafenib and is admitted day -8 in order to undergo lymphodepleting
chemotherapy with cyclophosphamide and fludara starting day -7.
- On day 0 patients receive TIL infusion and shortly after starts IL-2 infusion
continually following the decrescendo regimen.
- The patients will followed until progression or up to 5 years.
Title
- Brief Title: Vemurafenib and TIL Therapy for Metastatic Melanoma
- Official Title: T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma
Clinical Trial IDs
- ORG STUDY ID:
MM1414
- NCT ID:
NCT02354690
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Vemurafenib | Zelboraf, BRAF inhibitor | A |
Lymphodepleting chemotherapy | cyclophosphamide, fludarabine | A |
TIL infusion | Adoptive cell transfer, T cell therapy | A |
Interleukin-2 | IL-2 | A |
Purpose
Background:
Adoptive T cell therapy with tumor infiltrating lymphocytes (TILs) has been reported to
induce durable clinical responses in patients with metastatic melanoma. From patients own
tumor material T cells are extracted, expanded and activated in vitro in a 4-6 weeks culture
period. Before TIL infusion patients are preconditioned with a lymphodepleting
chemotherapeutic regimen. After TIL infusion, patients are treated with IL-2 to support T
cell activation and expansion in vivo.
The BRAF inhibitor is an approved treatment of metastatic melanoma and functions by
selectively inhibiting the BRAF mutated enzyme, consequently halting the proliferation of
tumor cells. Furthermore, in vitro tests have shown that vemurafenib has immunomodulatory
effects that are hypothesized to synergize with TIL therapy, which has been confirmed in
animal studies.
Objectives:
- To evaluate safety and feasibility when combining vemurafenib and ACT with TILs.
- To evaluate treatment related immune responses
- To evaluate clinical efficacy
Design:
- Patients will be screened with a physical exam, medical history, blood samples and ECG.
- Patients will start vemurafenib 960 mg BID and will continue during TIL preparation.
- 7 days after start of vemurafenib, patients will undergo surgery to harvest tumor
material for TIL production.
- Patient stops vemurafenib and is admitted day -8 in order to undergo lymphodepleting
chemotherapy with cyclophosphamide and fludara starting day -7.
- On day 0 patients receive TIL infusion and shortly after starts IL-2 infusion
continually following the decrescendo regimen.
- The patients will followed until progression or up to 5 years.
Trial Arms
Name | Type | Description | Interventions |
---|
A | Experimental | 7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2. | - Vemurafenib
- Lymphodepleting chemotherapy
- TIL infusion
- Interleukin-2
|
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed unresectable stage III or stage IV metastatic melanoma.
- Metastasis available for surgical resection (about 2 cm3) and residual measureable
disease after resection.
- Pathologically verified BRAF mutation.
- ECOG performance status 0-1.
- Life expectancy ≥ 3 months.
- No significant toxicity (CTC ≤ 1) from prior treatments.
- Adequate renal, hepatic and hematologic function.
- Women of childbearing potential (WOCBP) and men in a sexual relationship with a WOCBP
must be using an effective method of contraception during treatment and for at least 6
months after completion of treatment.
- Able to comprehend the information given and willing to sign informed consent.
Exclusion Criteria:
- Other malignancies, unless followed for ≥ 5 years with no sign of disease, except
squamous cell carcinoma or adequately treated carcinoma in situ colli uteri.
- Cerebral metastasis. Patients with previously treated CNS metastasis can participate
if surgically removed or treated with stereotactic radiotherapy if stable > 28 days
after treatment measured by MRI. Patients with asymptomatic and untreated CNS
metastasis can participate based on investigators evaluation.
- Patients with ocular melanoma.
- Previous treatment with a BRAF inhibitor.
- Severe allergies, history of anaphylaxis or known allergies to drugs administered.
- Serious medical or psychiatric comorbidity.
- QTc ≥ 450 ms.
- Clearance < 70 ml/min.
- Acute or chronic infection with e.g. HIV, hepatitis, tuberculosis
- Active autoimmune disease.
- Pregnant og nursing women.
- Need for immunosuppressive treatment, e.g. corticosteroids or methotrexate.
- Concomitant treatment with other experimental drugs.
- Patients with uncontrolled hypercalcemia
- More than four weeks must have elapsed since any prior systemic therapy at the time of
treatment
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of Reported Adverse Events |
Time Frame: | 0-40 weeks |
Safety Issue: | |
Description: | Determine the safety of the administration of vemurafenib in combination with TIL therapy including lymphodepleting chemotherapy and interleukin-2 treatment by collecting adverse events according to CTCAE v. 4.0. From start of treatment until 24 weeks after T cell infusion. |
Secondary Outcome Measures
Measure: | Treatment Related Immune Responses |
Time Frame: | 0-24 weeks |
Safety Issue: | |
Description: | Number of patients whose infusion product contained anti-tumor reactive T cells by in vitro testing.
Anti-tumor reactive T cells is defined by positive staining for two of the three markers (interferon gamma, tumor necrosis factor alpha and CD107a) in an intracellular cytokine staining using flow cytometry. |
Measure: | Objective Response Rate |
Time Frame: | Up to 12 months |
Safety Issue: | |
Description: | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
Measure: | Overall Survival |
Time Frame: | Up to 40 months |
Safety Issue: | |
Description: | Overall survival (OS), defined as the time from the start of treatment to death, will be described with the Kaplan-Meier curve. |
Measure: | Progression Free Survival |
Time Frame: | Up to 40 months |
Safety Issue: | |
Description: | Progression-free survival (PFS), defined as the time from start of treatment to disease progression, relapse or death due to any cause, whichever is earlier, will be described with the Kaplan-Meier curve.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Inge Marie Svane |
Last Updated
March 23, 2020